PETACH TIKVA, Israel, Oct. 7, 2014 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company’s CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014.
In addition to co-chairing the Cancer Therapeutics session, Dr. Fishman will deliver a presentation regarding Can-Fite’s drug, CF102, titled, “CF102 for the treatment of liver cancer: De-regulation of the Wnt signal transduction pathway.”
In pre-clinical and clinical studies in liver cancer patients, CF102 has demonstrated a robust anti-tumor effect via deregulation of the Wnt signaling pathway, known to mediate and control cell proliferation, resulting in apoptosis of liver cancer cells.
“I am grateful for the opportunity to co-chair the Cancer Therapeutics session and to present CF102 as a potential treatment for liver cancer at this prestigious international conference. This conference brings together researchers and key opinion leaders from around the world to learn about and discuss the latest developments in the fight against cancer,” stated Dr. Fishman.
CF102 is now entering Phase II trials in the U.S., Europe and Israel for the treatment of hepatocellular carcinoma, the most common form of liver cancer. The U.S. Food and Drug Administration has granted Orphan Drug Status to Can-Fite’s CF102 for this indication, and Israel’s Ministry of Health has approved CF102 for Compassionate Use in liver cancer patients.
